Contact Info

Solita – AI-powered IVF diagnostics for the global fertility clinic market

Solita is developing MetaEndo, a multi-layer IVF diagnostics platform that uses deep neural networks and clinical data to help fertility clinics to accurately detect implantation window. We target a global in-vitro fertilisation market exceeding USD 40 billion over the next decade, with a scalable SaaS and remote service model.

B2B software development

Who we are

AI, software and healthcare under one roof

Solita is a Lithuanian technology company that has been building digital solutions for clients of all sizes since 2018, with activities in data analysis, system architecture, performance engineering, programming and AI-based solutions.

Today Solita is focused on applying this software and AI expertise to healthcare. Together with leading reproductive medicine experts and research partners, we are creating MetaEndo – an AI-powered diagnostic system designed to support more personalised and efficient IVF treatment.

MetaEndo: AI-powered endometrial diagnostics for IVF

From complex data to clear clinical guidance

MetaEndo is a new personalised healthcare service that aims to improve IVF effectiveness, reduce treatment duration and increase the probability of pregnancy per cycle.

Using digital histological images of endometrial biopsies, MetaEndo applies deep neural networks and automatic decision-making algorithms to extract quantitative features and link them with each patient's clinical profile: age, infertility history, hormone status, laboratory tests, ultrasound data, progesterone levels and other biomarkers.

The result is a personalised decision-support report that helps clinicians better understand the endometrium, identify the individual "implantation window" and plan embryo transfer timing more precisely.

For fertility clinics

Designed to fit into your IVF workflow

MetaEndo is being developed as a remote, AI-enabled service for fertility clinics and IVF centers:

  • Single biopsy, local histology, digital upload – clinics use their existing pathology partners; only the digital slide and clinical data are uploaded to MetaEndo.
  • Online platform (SaaS) – clinicians access the service through a secure web interface, without geographic limitations.
  • Clear, structured reports – MetaEndo categorises endometrial receptivity (pre-receptive, receptive, post-receptive) and provides timing guidance around the implantation window.
  • Resource optimisation – by reducing repeated IVF cycles and unnecessary procedures, MetaEndo aims to improve clinic efficiency and cost-effectiveness.

If you are a fertility clinic, IVF center or diagnostic lab interested in piloting MetaEndo or integrating it into your workflow, please contact us – our clinical and technical team will be happy to discuss details.

For investors

Key figures (Solita UAB – operating company)

  • Founded in 2018, based in Kaunas, Lithuania
  • Revenue-generating since 2018 from B2B software development
  • EU grant funding for MetaEndo project: EUR 587,358.9 (non-dilutive)
  • Own funds invested via UAB Layer Pharma: EUR 304,993.1

AI-enabled IVF diagnostics in a fast-growing market

The global IVF market is estimated at around USD 19.5 billion in 2022 and is projected to grow to over USD 40 billion with a CAGR of about 7–8% over the coming years. Fertility clinics generate the majority of revenues and remain the primary channel for innovation.

Solita's value proposition to investors combines:

  • AI-powered IVF diagnostics – MetaEndo integrates clinical and histological data rather than focusing only on embryos, aiming for a more holistic view of the IVF process.
  • SaaS and remote service model – MetaEndo is commercialised as a cloud-based service, enabling scalable deployment across clinics and countries.
  • Established software revenues – Solita UAB is already a revenue-generating software and AI company; 100% of current sales come from IT services, providing a commercial base for MetaEndo development.
  • Differentiated competitive position – many existing AI IVF solutions concentrate on embryo evaluation only; MetaEndo's multi-layer approach is designed to also capture endometrial receptivity and patient-specific factors.

A Cyprus-registered holding company, "Solita Holding PLC", is intended to act as a capital markets platform, with a potential objective of admitting its shares to trading on the regulated Open Market segment of the German stock exchange.

Our technology and partnerships

Deep learning meets reproductive medicine

MetaEndo is being developed together with the Lithuanian University of Health Sciences (LSMU) and reproductive medicine specialists, who contribute clinical expertise, biopsy samples and outcome data.

The technology stack includes:

  • deep neural networks for automated analysis of digital endometrial histology;
  • machine-learning models that combine histology with genomics, microbiome, hormone and clinical data;
  • secure cloud infrastructure for remote, GDPR-compliant delivery of diagnostic reports.

Mission

Our mission is to make advanced endometrial diagnostics accessible to fertility clinics of all sizes, helping to:

  • increase the probability of pregnancy per IVF cycle,
  • reduce emotional and financial stress for patients,
  • and support clinicians with objective, AI-powered decision support.
Disclaimer

The information on this website is provided for general information purposes only. It does not constitute, and must not be construed as, an offer to sell or a solicitation of an offer to buy any securities of Solita Holding PLC or UAB Solita, nor as investment advice or a recommendation.

Any future admission of Solita Holding PLC shares to trading on German Open Market (Freiverkehr) segments would take place on exchange-regulated, non-EU-regulated markets, which have less stringent transparency and investor-protection requirements than EU-regulated markets. Investing in small, growth-stage companies is highly speculative and may result in the loss of the entire amount invested.